High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma

Simple Summary Oral cancer is a life-threatening disease and among the ten most common cancer types. Specific protein biomarkers in the blood of these patients may allow early tumor detection, earlier intervention and help to individualize therapy resulting in improved patient survival. This exploratory study analyzed the serum proteome with a highly reliable technology to define novel, non-invasive biomarkers of oral cancer. Our results showed important differences of the serum levels of 63 proteins in oral cancer patients vs. controls and of 121 proteins discriminating between patients before and after curative surgery. Our study proves the feasibility of this approach to establish novel serum biomarkers that help to improve the treatment of patients with oral cancer. Abstract Improved serological biomarkers are needed for the early detection, risk stratification and treatment surveillance of patients with oral squamous cell carcinoma (OSCC). We performed an exploratory study using advanced, highly specific, DNA-aptamer-based serum proteomics (SOMAscan, 1305-plex) to identify distinct proteomic changes in patients with OSCC pre- vs. post-resection and compared to healthy controls. A total of 63 significantly differentially expressed serum proteins (each p < 0.05) were found that could discriminate between OSCC and healthy controls with 100% accuracy. Furthermore, 121 proteins were detected that were significantly altered between pre- and post-resection sera, and 12 OSCC-associated proteins reversed to levels equivalent to healthy controls after resection. Of these, 6 were increased and 6 were decreased relative to healthy controls, highlighting the potential relevance of these proteins as OSCC tumor markers. Pathway analyses revealed potential pathophysiological mechanisms associated with OSCC. Hence, quantitative proteome analysis using SOMAscan technology is promising and may aid in the development of defined serum marker assays to predict tumor occurrence, progression and recurrence in OSCC, and to guide personalized therapies.

[1]  T. Salo,et al.  Stress induced phosphoprotein 1 overexpression controls proliferation, migration and invasion and is associated with poor survival in oral squamous cell carcinoma , 2023, Frontiers in Oncology.

[2]  Hao-Ping Liu,et al.  Identification of salivary autoantibodies as biomarkers of oral cancer with immunoglobulin A enrichment combined with affinity mass spectrometry , 2023, Proteomics.

[3]  Anca Maria Pop,et al.  The Use of Salivary Levels of Matrix Metalloproteinases as an Adjuvant Method in the Early Diagnosis of Oral Squamous Cell Carcinoma: A Narrative Literature Review , 2022, Current issues in molecular biology.

[4]  Nadezhda T. Doncheva,et al.  The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest , 2022, Nucleic Acids Res..

[5]  A. Galecki,et al.  Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes , 2022, Science Translational Medicine.

[6]  T. Libermann,et al.  Circulating proteomic profiles associated with endometriosis in adolescents and young adults. , 2022, Human reproduction.

[7]  Stephen A. Williams,et al.  A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk , 2022, Science Translational Medicine.

[8]  H. Otu,et al.  Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy , 2022, Kidney international reports.

[9]  Zhe S Chen,et al.  Proteomics technologies for cancer liquid biopsies , 2022, Molecular Cancer.

[10]  M. Affolter,et al.  Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications , 2022, Expert review of proteomics.

[11]  H. C. Beck,et al.  Recent Developments in Clinical Plasma Proteomics—Applied to Cardiovascular Research , 2022, Biomedicines.

[12]  Tzong-Ming Shieh,et al.  Salivary Exosome Proteomics and Bioinformatics Analysis in 7,12-Dimethylbenz[a]anthracene-Induced Oral Cancer with Radiation Therapy—A Syrian Golden Hamster Model , 2021, Diagnostics.

[13]  R. Bischoff,et al.  Non-Antibody-Based Binders for the Enrichment of Proteins for Analysis by Mass Spectrometry , 2021, Biomolecules.

[14]  A. Hingorani,et al.  Synergistic insights into human health from aptamer- and antibody-based proteomic profiling , 2021, Nature Communications.

[15]  D. Schuppan,et al.  Liquid biomarkers for fibrotic NASH - progress in a complex field. , 2021, Journal of hepatology.

[16]  M. D. Del Bigio,et al.  Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes , 2021, International journal of molecular sciences.

[17]  Stephen A. Williams,et al.  Plasma proteins, cognitive decline, and 20‐year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[18]  T. Sasahira,et al.  SERPINE2 is an oral cancer-promoting factor that induces angiogenesis and lymphangiogenesis , 2021, International Journal of Clinical Oncology.

[19]  Jie Huang,et al.  Advances in Aptamer-Based Biomarker Discovery , 2021, Frontiers in Cell and Developmental Biology.

[20]  S. Jiang,et al.  Insulin-like growth factor binding protein 3 promotes radiosensitivity of oral squamous cell carcinoma cells via positive feedback on NF-κB/IL-6/ROS signaling , 2021, Journal of experimental & clinical cancer research : CR.

[21]  A. Bosserhoff,et al.  Identification of oral squamous cell carcinoma markers MUC2 and SPRR1B downstream of TANGO , 2021, Journal of Cancer Research and Clinical Oncology.

[22]  Bridget A. Tripp,et al.  Proteome-Wide Analysis using SOMAscan Identifies and Validates Chitinase-3-Like Protein 1 as a Risk and Disease Marker of Delirium Among Older Adults Undergoing Major Elective Surgery. , 2021, The journals of gerontology. Series A, Biological sciences and medical sciences.

[23]  O. Kepp,et al.  Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients , 2021, Oncoimmunology.

[24]  T. Yoneda,et al.  High-mobility group box 1 induces bone destruction associated with advanced oral squamous cancer via RAGE and TLR4. , 2020, Biochemical and biophysical research communications.

[25]  A. Reiner,et al.  Comparison of Proteomic Assessment Methods in Multiple Cohort Studies , 2020, Proteomics.

[26]  T. Libermann,et al.  Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation , 2019, Scientific Data.

[27]  F. Finkernagel,et al.  Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma , 2019, Front. Oncol..

[28]  F. Finkernagel,et al.  Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment , 2019, Theranostics.

[29]  A. Fucic,et al.  Androgen Receptor as a Biomarker of Oral Squamous Cell Carcinoma Progression Risk , 2019, AntiCancer Research.

[30]  Woochang Lee,et al.  Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer , 2018, Journal of Korean medical science.

[31]  J. Fox,et al.  Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer , 2018, Nature Communications.

[32]  M. Shakeri,et al.  Overexpression of High-Mobility Motor Box 1 in the Blood and Tissues of Patients with Head and Neck Squamous Cell Carcinoma , 2018, Iranian journal of otorhinolaryngology.

[33]  Sherilyn J. Sawyer,et al.  Stability and reproducibility of proteomic profiles measured with an aptamer-based platform , 2018, Scientific Reports.

[34]  T. Libermann,et al.  Tie2 protects the vasculature against thrombus formation in systemic inflammation , 2018, The Journal of clinical investigation.

[35]  V. Alves,et al.  External validation of the AJCC Cancer Staging Manual, 8th edition, in an independent cohort of oral cancer patients. , 2017, Oral oncology.

[36]  A. Pabst,et al.  Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: A review of the literature. , 2017, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[37]  T. Kondo,et al.  Proteomic study of hepatocellular carcinoma using a novel modified aptamer-based array (SOMAscan™) platform. , 2017, Biochimica et biophysica acta. Proteins and proteomics.

[38]  Sheng F Huang,et al.  Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[39]  M. Nagata,et al.  Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma. , 2015, Molecular and clinical oncology.

[40]  Hongchen Liu,et al.  Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma , 2015, PloS one.

[41]  Eric P. Hoffman,et al.  Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy , 2015, Proceedings of the National Academy of Sciences.

[42]  L. Kowalski,et al.  Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells , 2015, Oncotarget.

[43]  Stephen A. Williams,et al.  Validation of a blood protein signature for non-small cell lung cancer , 2014, Clinical Proteomics.

[44]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[45]  M. Mason,et al.  Proteomics Analysis of Cancer Exosomes Using a Novel Modified Aptamer-based Array (SOMAscanTM) Platform , 2014, Molecular & Cellular Proteomics.

[46]  Jen-Yang Tang,et al.  High LC3 expression correlates with poor survival in patients with oral squamous cell carcinoma. , 2013, Human pathology.

[47]  Ning Geng,et al.  Angiopoietin-2 expression is correlated with angiogenesis and overall survival in oral squamous cell carcinoma , 2013, Medical Oncology.

[48]  M. Hou,et al.  High nuclear protein kinase CβII expression is a marker of disease recurrence in oral squamous cell carcinoma. , 2012, Anticancer research.

[49]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[50]  A. Santarelli,et al.  Analysis of tissue and salivary nicotinamide N-methyltransferase in oral squamous cell carcinoma: basis for the development of a noninvasive diagnostic test for early-stage disease , 2012, Biological chemistry.

[51]  H. Moch,et al.  Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma , 2011, Cancer.

[52]  A. García-García,et al.  What real influence does the proto-oncogene c-myc have in OSCC behavior? , 2011, Oral oncology.

[53]  I. Asahina,et al.  Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. , 2011, Oral oncology.

[54]  M. Stack,et al.  Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas , 2011, Molecular and Cellular Biochemistry.

[55]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, PloS one.

[56]  Bao-Ling Adam,et al.  Proteomic identification of serum biomarkers for head and neck cancer surveillance , 2009, The Laryngoscope.

[57]  R. Nagler,et al.  A comprehensive salivary analysis for oral cancer diagnosis , 2007, Journal of Cancer Research and Clinical Oncology.

[58]  P. Ding,et al.  Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma. , 2005, International journal of molecular medicine.

[59]  Robert Tibshirani,et al.  The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers , 2004, Clinical Cancer Research.

[60]  V. Hundley,et al.  The importance of pilot studies. , 2002, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[61]  D. Ciavarella,et al.  Potential Salivary Proteomic Markers of Oral Squamous Cell Carcinoma. , 2016, Cancer genomics & proteomics.

[62]  B. Adam,et al.  Identification of patients with head and neck cancer using serum protein profiles. , 2004, Archives of otolaryngology--head & neck surgery.